Assessing the safety and effects of HRS-1301 in healthy individuals
Official title: A Phase I, Randomized, Double-blind and Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1301 Following Single and Multiple Dose Administration in Healthy
Run by Shandong Suncadia Medicine Co., Ltd. · NCT06857253 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new drug called HRS-1301 in healthy people to see how safe it is and how it works in the body.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 82 (estimated) |
| Sponsor | Shandong Suncadia Medicine Co., Ltd. Industry-sponsored |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06857253 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy males and females aged 18 to 55 who meet the inclusion criteria.
✕Probably not a fit
Patients with gastrointestinal, liver, or kidney diseases, or those with a history of severe trauma or surgeries in the recent past may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-1301 in healthy subjects through both single and multiple dose administrations. It consists of two parts and plans to enroll 82 participants, with potential adjustments to sample size and treatment duration based on emerging data. The study aims to gather important information on how the drug behaves in the body and its overall safety profile.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of HRS-1301's safety and effectiveness, paving the way for future treatments for hyperlipidemia.
How similar studies have gone: While this study focuses on a specific drug, similar studies assessing the safety and pharmacokinetics of new treatments have shown promise in the past.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Healthy male and female subjects must be at least 18 years old and no more than 55 years old on the date of signing the ICF. 2. The female subjects must be non-pregnant or non-childbearing potential. 3. Subjects must understand the study procedures and methods, voluntarily participate in this study and sign the ICF in person. Exclusion Criteria: 1. Have a gastrointestinal, liver or kidney disease or other condition known to affect drug absorption, distribution, metabolism and excretion or to reduce adherence, as determined by the investigator. 2. Those who had severe trauma or had undergone surgery within 3 months prior to screening, or planned to undergo surgery during the trial. 3. Have a history of repeated drug allergies. 4. People who have used any drug in the 2 weeks prior to screening. 5. Those who received live (attenuated) vaccine within 4 weeks prior to screening or planned to receive it during the trial.
Where it's running
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Ying Wang
- Email: ying.wang.yw30@hengrui.com
- Phone: +86-15052585832
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Enlicitide (MK-0616) for adults with high cholesterol in India
This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.
-
HRS-7249 extension study for people with high triglycerides
This extension study tests whether repeat injections of HRS-7249 are safe and keep triglyceride levels low in adults who previously completed the parent study or have high fasting triglycerides.
-
Bacillus subtilis and Enterococcus faecium Probiotic Plus Lipid-Lowering Therapy for HTG-AP
This trial tests whether adding a probiotic capsule to standard lipid-lowering therapy helps people with mild HTG-AP see lower triglycerides and better recovery.
-
EHR-guided LDL cholesterol optimization after a heart event
A pharmacist-guided program using electronic health records to help adults in Alberta reach LDL goals after a heart event by adjusting medications and ordering tests.
-
Spermidine supplement for lipid and weight changes in adults with obesity and high cholesterol
This study tests whether taking spermidine daily for 1 month can improve blood lipids and body weight in adults who are overweight or obese with high cholesterol, while monitoring safety.
-
Digital health platform to help prevent and manage high blood pressure, lipids, and kidney and heart disease
This trial tests a mobile digital health platform to help people with hypertension, dyslipidemia, and related conditions in New Taipei City see if the platform improves blood pressure, cholesterol, and kidney health.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.